1Parkin DM,Bray F,Ferlay J,et al.Estimating the world cancerburden:Globocan 2000[J].Int J Cancer,2001,94(2):153.
2Ramalingam S,Pawlish K,Gadgeel S,et al.Lung cancer in youngpatients:analysis of a surveillance,epidemiology,and end resultsdatabase[J].J Clin Oncol,1998,16(2):651.
4Icard P,Regnard JF,Napoli S,et al.Primary lung cancer in youngpatients:a study of 82surgically treated patients[J].Ann ThoracSurg,1992,54(1):99.
5Yang P,Visbal A,Ebbert J,et al.Characteristics of lung cancerpatients who were diagnosed younger than 50or older than 8Oyears of age[J].Lung Cancer,2005,49(2):22.
6Gadgeel SM,Ramalingam S,Cummings G,et al.Lung cancer inpatients<50years of age:the experience of an academic multidis-ciplinary program[J].Chest,1999,115(5):1232.
7Sawada S,Komori E,Nogami N,et al.Advanced age is not corre-lated with either short-term or long-term postoperative results inlung cancer patients in good clinical condition[J].Chest,2005,128(3):1557.
8Yazgan S,Gursoy S,Yaldiz S,et al.Outcome of surgery for lungcancer in young and elderly patients[J].Surg Today,2005,35(10):823.
9Green LS,Fortoul TI,Ponciano G,et al.Bronchogenic cancer inpatients under 40years old[J].Chest,1993,104(5):1477.
7Rosell R, Gervais R, Vergnenegre A, et al. Erlotinib versuschemotherapy (CT) in advanced non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemo-therapy (EURTAC) phase III randomized trial [J]. J Clin Oncol, 2011, 29(15): abstract 7503.
8Wang S, Wong ML, Hamilton N, et al. Impact of cornorbidity on non small cell lung cancer treatment veterans [J]. J Clin 0ncol,2012,30(13) :1447-1455.
10Irisa K, Masago K, Togashi Y, et al. Significance of pretreatment comorbidities in elderly patients with advanced non-small-cell lung cancer treated with hemotherapy or epidermal growth factor receptortyrosine kinase inhibitor [J]. Med 0ncol,2012,29(3) : 185-192.
